WallStSmart

Innovative Industrial Properties Inc (IIPR)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 1915% more annual revenue ($5.36B vs $265.95M). IIPR leads profitability with a 44.5% profit margin vs -2.7%. IIPR earns a higher WallStSmart Score of 52/100 (C-).

IIPR

Buy

52

out of 100

Grade: C-

Growth: 2.0Profit: 7.5Value: 6.0Quality: 5.0

LINE

Avoid

35

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IIPR.

LINEUndervalued (+75.9%)

Margin of Safety

+75.9%

Fair Value

$161.27

Current Price

$39.32

$121.95 discount

UndervaluedFair: $161.27Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IIPR4 strengths · Avg: 9.5/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Profit MarginProfitability
44.5%10/10

Keeps 45 of every $100 in revenue as profit

Operating MarginProfitability
51.3%10/10

Strong operational efficiency at 51.3%

P/E RatioValuation
13.9x8/10

Attractively priced relative to earnings

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

IIPR4 concerns · Avg: 2.5/10
Market CapQuality
$1.56B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.3%3/10

ROE of 6.3% — below average capital efficiency

Revenue GrowthGrowth
-13.1%2/10

Revenue declined 13.1%

EPS GrowthGrowth
-22.1%2/10

Earnings declined 22.1%

LINE4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Return on EquityProfitability
-1.8%2/10

ROE of -1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IIPR

The strongest argument for IIPR centers on Price/Book, Profit Margin, Operating Margin. Profitability is solid with margins at 44.5% and operating margin at 51.3%.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : IIPR

The primary concerns for IIPR are Market Cap, Return on Equity, Revenue Growth.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Key Dynamics to Monitor

IIPR profiles as a declining stock while LINE is a turnaround play — different risk/reward profiles.

LINE is growing revenue faster at 0.4% — sustainability is the question.

IIPR generates stronger free cash flow (53M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IIPR scores higher overall (52/100 vs 35/100), backed by strong 44.5% margins. LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innovative Industrial Properties Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

Innovative Industrial Properties, Inc. is a self-advising Maryland corporation focused on acquiring, owning, and managing specialty properties leased to experienced state-licensed operators for their regulated medical cannabis facilities.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.

Visit Website →

Want to dig deeper into these stocks?